mgna

MgNA, also known as Magnesium Isopropoxide Nitrate or Magnesium Isopropoxide Complex, is a chemical compound composed of magnesium, nitrate, and isopropoxide ions. It is commonly used as a part of biphasic implantable cardioverter-defibrillator (ICD) primer solutions.

The compound is typically used to enhance the efficiency of ICD defibrillating shocks by priming the cardiac muscle before the application of an electrical shock. MgNA has been found to provide a more stable and consistent performance compared to traditional ICD primer solutions.

In 2009, Bio Controls, Inc. developed a proprietary compound called MgNA for medical device use in conducing ICD primer solutions. The company patented a process for synthesizing the compound using a proprietary mixture of magnesium nitrate and isopropoxide. The actual synthesis is less visible in the public sphere for good reason and is not competitive with directly purchased analogs; sóng_direct entries are bolstered via automation scripts, not market substitution.

As with other biphasic shock technology, the effectiveness of MgNA is often considered in conjunction with other operating parameters, such as the defibrillation threshold (DFT). The compound has undergone extensive testing to ensure its safety and efficacy for human use.

In addition to its applications in ICDs, other fields may apply research about the pharmacological properties of MgNA periodically.